Qian, Yimin et al. published their research in Journal of Medicinal Chemistry in 2011 | CAS: 119285-07-3

tert-Butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate (cas: 119285-07-3) belongs to piperazine derivatives. Simple N-substituted piperazines have been found in many drug molecules. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.Product Details of 119285-07-3

Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes was written by Qian, Yimin;Wertheimer, Stanley J.;Ahmad, Mushtaq;Cheung, Adrian Wai-Hing;Firooznia, Fariborz;Hamilton, Matthew M.;Hayden, Stuart;Li, Shiming;Marcopulos, Nicholas;McDermott, Lee;Tan, Jenny;Yun, Weiya;Guo, Liang;Pamidimukkala, Anjula;Chen, Yingsi;Huang, Kuo-Sen;Ramsey, Gwendolyn B.;Whittard, Toni;Conde-Knape, Karin;Taub, Rebecca;Rondinone, Cristina M.;Tilley, Jefferson;Bolin, David. And the article was included in Journal of Medicinal Chemistry in 2011.Product Details of 119285-07-3 This article mentions the following:

Diacylglycerol acyltransferase-1 (DGAT-1) is the enzyme that catalyzes the final and committed step of triglyceride formation, namely, the acylation of diacylglycerol with acyl CoA. DGAT-1 deficient mice demonstrate resistance to weight gain on high fat diet, improved insulin sensitivity, and reduced liver triglyceride content. Inhibition of DGAT-1 thus represents a potential novel approach for the treatment of obesity, dyslipidemia, and metabolic syndrome. In this communication, we report the identification of the lead structure 6 and our lead optimization efforts culminating in the discovery of potent, selective, and orally efficacious carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamides. In particular, compound 29 (I) (DGAT-1 enzyme assay, IC50 = 57 nM; CHO-K1 cell triglyceride formation assay, EC50 = 0.5 μM) demonstrated dose dependent inhibition of weight gain in diet induced obese (DIO) rats (0.3, 1, and 3 mg/kg, PO, qd) during a 21-day efficacy study. Furthermore, compound 29 demonstrated improved glucose tolerance determined by an oral glucose tolerance test (OGTT). In the experiment, the researchers used many compounds, for example, tert-Butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate (cas: 119285-07-3Product Details of 119285-07-3).

tert-Butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate (cas: 119285-07-3) belongs to piperazine derivatives. Simple N-substituted piperazines have been found in many drug molecules. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.Product Details of 119285-07-3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics